射频消融治疗复发性肝癌疗效及预后因素分析

摘要

Based on both domestic and abroad research results concerning the local therapeutic efficacy, influence factors, survival time and prognosis of radiofrequency ablation (RFA) in treating recurrent hepatocellular carcinoma (HCC), this paper aims to make a review of medical literatures about RFA treatment of recurrent HCC that were published in Chinese and in English during the period from 2005 to 2014, and to analyze the related factors that may influence the local therapeutic efficacy and survival rate. The results indicate that the recurrent tumor size, tumor number, recurrence interval, serum alpha fetoprotein (AFP) level, serum prothrombin, etc. are important factors that will affect the therapeutic efficacy of recurrent HCC. At the same time, the results point out that the study of imaging predictors can help suggest the different recurrent types, which is very useful in making individualized follow-up strategy and in monitoring tumor recurrence. Local treatment, with RFA being the main method, together with comprehensive therapies, including other new technologies and new drugs, will improve the current clinical situation in treating recurrent HCC.%基于国内外对射频消融（RFA）治疗复发性肝癌的局部疗效、影响因素及生存期预后因素的研究成果，本文回顾2005—2014年RFA治疗复发性肝癌的中英文文献，分析并总结影响局部疗效及整体生存率的相关因素，得出复发肿瘤大小、复发肿瘤数目、复发间期、血清甲胎蛋白、血清凝血酶原等是影响复发性肝癌治疗效果的重要因素。同时指出对影像学预测指标进行研究，有助于提示不同复发类型、帮助临床制定个体化的随访策略，监测肿瘤复发；治疗时采取以RFA为主的局部治疗方法与其他新技术、新药物有机配合的综合治疗措施，将提高复发性肝癌的治疗现状。